dc.contributor.author | Cokugras, Haluk | |
dc.contributor.author | Kasapcopur, Ozgur | |
dc.contributor.author | Arisoy, Nil | |
dc.contributor.author | Kilic, Omer | |
dc.contributor.author | Camcioglu, Yildiz | |
dc.contributor.author | Akcakaya, Necla | |
dc.date.accessioned | 2021-03-03T08:11:23Z | |
dc.date.available | 2021-03-03T08:11:23Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Kilic O., Kasapcopur O., Camcioglu Y., Cokugras H., Arisoy N., Akcakaya N., "Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease?", RHEUMATOLOGY INTERNATIONAL, cilt.32, sa.9, ss.2675-2679, 2012 | |
dc.identifier.issn | 0172-8172 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_162c0270-671b-4c7e-ab5b-a57e49af52bc | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/20267 | |
dc.identifier.uri | https://doi.org/10.1007/s00296-011-2030-8 | |
dc.description.abstract | To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-alpha treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 +/- A 3.96 years (4.08-19.41 years), mean duration of illness was 5.86 +/- A 3.77 years (0.66-15 years), and the mean duration of anti-TNF-alpha treatment was 2.41 +/- A 1.47 years (0.6-7 years). Anti-TNF-alpha agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-alpha therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-alpha treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-alpha treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ROMATOLOJİ | |
dc.title | Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease? | |
dc.type | Makale | |
dc.relation.journal | RHEUMATOLOGY INTERNATIONAL | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 32 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 2675 | |
dc.identifier.endpage | 2679 | |
dc.contributor.firstauthorID | 42377 | |